Leerink downgrades Synageva BioPharma, cites lack of visibility

|About: Synageva BioPharma Corp. (GEVA)|By:, SA News Editor

Leerink downgrades Synageva BioPharma (GEVA) to Market Perform from Outperform.

Analyst Joseph Schwartz cites "lack of news flow and visibility into the market opportunity for sebelipase alfa."

Schwartz also says the stock may remain "relatively rangebound until ARISE pivotal trial data" due in H2 2014 or H1 2015.

Price target cut to $62 from $66.